ReviewBlood2015
How I treat hypereosinophilic syndromes.
Review in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00044304 (Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients With Myeloid and/or Steroid-Refractory Hypereosinophilic Syndrome), which is not on this map. Cited by 133 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients With Myeloid and/or Steroid-Refractory Hypereosinophilic Syndrome
Who cites it
133 citing papers in PubMed, 3 syntheses or guidelines pooled it, 280 citations in OpenAlex.
- Renal involvement in hypereosinophilic syndrome: a systematic review with narrative synthesis of pathology, diagnosis, and therapy.Frontiers in immunology · 2026Pooled it
- French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes.Orphanet journal of rare diseases · 2023Guideline
- Eosinophils and eosinophil-associated diseases: An update.The Journal of allergy and clinical immunology · 2018Pooled it
- Long-Term Efficacy and Safety of Benralizumab Treatment for PDGFRA-Negative Hypereosinophilic Syndrome.The journal of allergy and clinical immunology. In practice · 2025Trial
- Phase II trial of imatinib mesylate in patients with PDGFRA/B-negative hypereosinophilic syndrome.British journal of haematology · 2024Trial
- Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome.Frontiers in immunology · 2022Trial
- Trial
- Mechanisms of glucocorticoid resistance in hypereosinophilic syndromes.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2019Trial
- Benralizumab forThe New England journal of medicine · 2019Trial
- Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.The journal of allergy and clinical immunology. In practiceTrial
- Hypereosinophilic Syndrome Subtype Predicts Responsiveness to Glucocorticoids.The journal of allergy and clinical immunology. In practiceTrial
- Incidence and prevalence of hypereosinophilic syndrome in the United States: A retrospective claims database study.The World Allergy Organization journal · 2026Article
- Patient Journey, Treatment Patterns, and Disease Burden of Patients With Idiopathic Hypereosinophilic Syndrome.EJHaem · 2026Article
- Hypereosinophilic syndrome mimicking gastric malignancy: considerations on the challenging diagnosis-a case report and review of the literature.Journal of medical case reports · 2026Review
- Article
- Redefining Hematology Referral Thresholds for Eosinophilia.European journal of haematology · 2026Review
- Bilateral temporal arteritis with multiorgan eosinophilic infiltration treated with IL-5 targeted antibody.Rheumatology international · 2026Review
- Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (FIP1L1::PDGFRA) complicated by Loeffler's endocarditis leading to stroke.BMC neurology · 2026Article
- Molecular Pathogenesis and Targeted Therapies for Myeloproliferative Hypereosinophilic Neoplasms.Current hematologic malignancy reports · 2026Review
- Dupilumab-Related Hypereosinophilia in Patients Treated for Type 2 Diseases: Evidence from a 24-Month Prospective Real-Life Study.Journal of clinical medicine · 2026Article
73 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Hypereosinophilic syndromes (HESs) are a group of rare disorders characterized by peripheral blood eosinophilia of 1.5 × 10(9)/L or higher and evidence of end organ manifestations attributable to the eosinophilia and not otherwise explained in the clinical setting. HESs are pleomorphic in clinical presentation and can be idiopathic or associated with a variety of underlying conditions, including allergic, rheumatologic, infectious, and neoplastic disorders. Moreover, the etiology of the eosinophilia in HESs can be primary (myeloid), secondary (lymphocyte-driven), or unknown. Although corticosteroids remain the first-line therapy for most forms of HESs, the availability of an increasing number of novel therapeutic agents, including tyrosine kinase inhibitors and monoclonal antibodies, has necessarily altered the approach to treatment of HESs. This review presents an updated treatment-based approach to the classification of patients with presumed HES and discusses the roles of conventional and novel agents in the management of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.